论文部分内容阅读
目的:比较化疗敏感性不同弥漫性大B细胞淋巴瘤的蛋白质表达差异,寻找可反映大B细胞淋巴瘤化疗敏感性的标志物。方法:通过肿瘤药物敏感试验选取化疗高敏感性和低敏感性大B细胞淋巴瘤组织,进行蛋白质组学比较研究后得出差异表达蛋白;对在高敏感组中高表达的埃兹蛋白(Ezrin)进一步行免疫印迹验证,应用免疫组化技术检测在临床病例中的表达情况。结果:建立了化疗高敏感和低敏感大B细胞淋巴瘤差异表达蛋白质凝胶2D图谱,鉴定了28种差异表达蛋白,发现Ezrin蛋白在化疗高敏感组表达高于低敏感组,免疫印迹和免疫组化结果也进一步证实了Ezrin的这一表达状态。结论:Ezrin蛋白表达在化疗敏感性不同大B细胞淋巴瘤中存在差别,可能作为预测淋巴瘤化疗敏感性的候选标志物。
OBJECTIVE: To compare the protein expression differences between different chemotherapy-sensitive diffuse large B-cell lymphomas and find markers that can reflect the chemosensitivity of large B-cell lymphomas. METHODS: High-sensitivity and low-sensitivity large B-cell lymphoma tissues were treated with chemotherapy sensitivity tests for tumors. Differentially expressed proteomics was used to obtain differentially expressed proteins. Ezrin was highly expressed in highly sensitive groups. Further Western blot validation was performed and immunohistochemical techniques were used to detect expression in clinical cases. RESULTS: The gel 2D maps of differentially expressed proteins of high-sensitivity and low-sensitivity large B-cell lymphomas were established. 28 differentially expressed proteins were identified. The expression of Ezrin protein in the highly sensitive chemotherapy group was higher than that in the low-sensitivity group. Immunoblotting and immunization were found. The grouping results further confirmed the expression status of Ezrin. CONCLUSION: The expression of Ezrin protein is different in chemosensitivity in different large B-cell lymphomas, which may be used as a candidate marker for predicting chemosensitivity of lymphoma.